anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Colorectal cancer (CRC) is a common and deadly tumor. FK506-binding protein 5 (FKBP5) is associated with some cancers, but the role of FKBP5 in CRC is not clear. The present study aimed to reveal the relationship between FKBP5 and CRC and to uncover the roles of FK506 in CRC. In total, 96 CRC patients were recruited. Survival analysis was conducted using the Kaplan-Meier method and COX regression analyses. Bioinformatics analyses were performed to explore the functions of FKBP5. The mechanisms of FKBP5 and the roles of FK506 in CRC progression were clarified by immunohistochemistry, MTS, scratch assay, transwell and flow cytometric analyses via in vitro and in vivo experiments. FKBP5 was overexpressed in 77 cancer tissues compared to that in matched normal tissues, and the overall survival rate of these patients was relatively shorter. Bioinformatics analyses showed that FKBP5 regulates proliferation, invasion, migration, epithelial-mesenchymal transition and nuclear factor-kappa B (NF-κB) signaling. The upregulation or downregulation of FKBP5 dramatically increases or decreases the proliferation, invasion and migration abilities of CRC cells. The expression of NF-κB, inhibitor B kinase α, matrix metalloproteinase-2 and metalloproteinase-9 positively correlated with FKBP5. FK506 inhibits the progression of CRC via the FKBP5/NF-κB signaling pathway. Our study identified a regulatory role for FKBP5 in CRC progression. Therefore, targeting FKBP5 may provide a novel treatment approach for CRC. FK506 can inhibit the progression of CRC by restraining the FKBP5/NF-κB signaling pathway and is expected to become a new drug for the treatment of CRC.
Systemic inflammation is important in obstructive sleep apnea (OSA) pathophysiology and its comorbidity. The objective of this study was to investigate how early biomarkers of inflammation may be altered in OSA patients. To complete this goal the investigators assessed the circulating levels of four inflammatory markers, hs-C-reactive protein (hs-CRP), Fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) in a representative population of consecutively enrolled, untreated and otherwise healthy subjects with a clinical suspicion of obstructive sleep apnea. A secondary objective was to investigate any correlation between these markers with clinical and polysomnographic (PSG) parameters of these subjects.Subjects who had undergone a PSG for OSA diagnosis were recruited. Patients with known comorbidities were excluded from the study. Included patients were grouped according to apnea-hypopnea index (AHI) as mild, moderate and severe. Patients with AHI \< 5 served as control group. Demographic, PSG data, serum levels of hs-CRP, fibrinogen, ESR and UA were measured and compared between groups.
This research aims at assessing and fine tuning the effectiveness of a unique tool for online guidance of neural rehabilitation. The tool monitors patient attention level and guides the therapist online regarding the effectiveness of the current exercise employed. It is well established that maintaining a high level of attention plays a major role in the clinical outcome in rehabilitation. The monitoring is achieved using a cheap and simple to use EEG system and a breakthrough signal processing algorithm. The feedback provides the caregiver and patient with online information regarding the effectiveness of attention recruited during a given exercise. Furthermore, the investigators are developing and fine-tuning a set of guidelines to attain optimal attention levels. These guide lines include : Choosing an appropriate goal/movement for each patient; Regulating the optimal degree of effort by changing the difficulty level of the exercise, changing the exercise or suggesting a short rest period; Integrating supportive exercises such as stretches, strengthening of stabilizers normalization of muscle tone, sensory stimulation etc. which may enhance the performance of the target goal/movement; Motivating patients to exert more effort; And taking advantage of the quality control aspect of the BEI index in-order to augment attention of both therapist and patient.
Acute kidney injury (AKI) is a common cause of excess morbidity and mortality amongst patients with long term conditions, and is a common finding in patients admitted acutely into hospital. Although the disease commonly develops in the community there is little evidence to guide identification of patients at risk or how best to educate healthcare workers in primary care to improve the care of patients at risk of AKI. We hypothesise firstly that: an AKI educational intervention in primary care can be delivered to healthcare practitioners with high integrity, and secondly that: an AKI educational intervention delivered in primary care will result in a decreased incidence of AKI in the community. To test this we will build on pilot work that detects high-AKI risk patients and provides education for healthcare workers and at-risk patients. The study will bring together novel informatics, and education programme for primary healthcare workers along with patient information and guidance. Recruitment will be at the practice level and will take place after the delivery of the face to face educational intervention. Recruited practices will have their high risk AKI patients identified using web based software, and GPs will be encouraged, where clinically appropriate, to contact patients with an educational leaflet advising them how to prevent AKI by stopping medications under certain circumstances. In addition a variety of associated biomedical data will be obtained from practice IT systems to identify the preceding incidence of AKI in any recruited practice. Eighteen months after the delivery of the education intervention the incidence of AKI in each practice will again be determined to examine the effect of the educational intervention on AKI incidence. The fidelity of delivery of the education intervention will also be studied using qualitative techniques. Power calculations suggest that 36 practices will need to participate to detect a 25% reduction in AKI incidence. We anticipate that this programme will effectively reduce AKI community incidence and will be of significant interest to commissioners. Study findings will be disseminated through a variety of avenues including through structures established by NHS England to support improvements in AKI management.
Chinese medicinal herb weight losing cream comprises the following components by mass: 2-8 parts of hedera helix extract, 2-4 parts of seaweed extract, 3-6 parts of oenothera biennis seed extract, 3-5 parts of green tea polyphenols, 2-4 parts of safflower extract, 2-5 parts of calendula extract, 3-8 parts of antioxidant, 1-3 parts of vitamin E and 60-80 parts of deionized water. The antioxidant is liquorice, Chinese gall or prune extract. Active ingredients of the Chinese medicinal herb weight losing cream are all extracted from plants, so that the Chinese medicinal herb weight losing cream does not contain pharmaceutical ingredients. The Chinese medicinal herb weight losing cream is absorbed by the skin by being spread on the skin to improve microcirculation of skin tips, promote degradation of subcutaneous fat cells and inhibit growth of the fat cells. The Chinese medicinal herb weight losing cream is environment-friendly. By means of the Chinese medicinal herb weight losing cream, people can lose weight under the relatively healthy situation.
Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
The subjects receive Baby EAR circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Jackson-Rees (JR) circuit and the procedure will be repeated.
The management of HIV is mainly represented by its commorbidities (cardio-vascular disease, nephrologic, neurologic, osteo-articular disease, chronic hepatitis and cancer no linked to immunodepression). COPD prevalence has never been studied in HIV population. In consequence, there is no guideline about the screening, treatment or follow-up of COPD in HIV patients. However this population seems particularly at risk to develop COPD because of high tobacco consumption and accelerate ageing. Thus, we need an epidemiologic study to understand the prevalence of COPD in HIV population in order to organize a specific screening and follow-up. This is supported by an improvement of COPD if early managed. On top of that, COPD screening will increase awareness of HIV patients on the problematic of tobacco consumption.
The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
A  cannabis  composition is disclosed. The  cannabis  composition comprises a  cannabis  extract, which comprises a  cannabis  phytocompound. A functional composition comprising the  cannabis  composition and a carrier is also provided, and adapted for administration to a subject via topical or oral application. A method of preparing the functional composition is also provided. A method of ameliorating a condition with the functional composition is further provided, and comprises administering the functional composition to a subject in an amount effective to elicit a biological response from the subject. The  cannabis  composition can be a multi-hemp extract composition. The multi-hemp extract composition generally comprises a first hemp component comprising a hemp dehydrate, a second hemp component different from the first hemp component, with the second hemp component comprising a hemp juice, and a third hemp component different from the first and second hemp components, with the third hemp component comprising a hemp extract.
The present invention belongs to the technical field of medical preparation through chemical synthesis. The present invention relates to a route of the chemical synthesis of a compound with platelet aggregation inhibiting activity and a method for preparing the compound. The present invention also relates to an external test of the platelet aggregation inhibiting activity of the compound. A Bron method is adopted, and a platelet aggregation device is utilized to measure the platelet aggregation inhibiting activity of the compound, wherein the IC50 of the compound 1-ortho-chlorophenyl-m-bromo-benzoyl-1, 2, 3, 4-tetrahydroisoquinoline-(TQP-3) is 0.206 (+/-) 0.033 nmol/L, and the activity of the compound is much higher than that of aspirin (the IC50 of which is 9.673 (+/-) 3.285 nmol/L). The structure of the compound of the present invention is obviously different from that of the existing platelet aggregation inhibiting medicines, such as inolin, ticlopidine, clopidogrel, aspirin, etc. The compound TQP-3 has strong medicinal activity of inhibiting platelet aggregation and is expected to be developed into a novel medicine for inhibiting platelet aggregation, which can be used as a thrombus inhibiting medicine for treating myocardial infarction, cerebral apoplexy, thrombi, etc.
The goal is to develop a mHealth App using smartphone embedded sensors to objectively collect physical function data in individuals with knee osteoarthritis (KOA) in the context of daily life. It will be performed technical development of an internet-interactive App to collect, analyze and transfer the subjects' data. As a proof-of-concept, the mHealth App will execute algorithms that automate deployment of three well-established physical function tests. In a laboratory setting, it will be evaluated usability, acceptability and reliability of the mHealth App compared with traditional performance tests among focus groups of individuals with KOA. It will then evaluate its usability and acceptability when used in the participants' home environments. As an early indicator of construct validity, it will be examined if the physical function test measurements can detect diurnal variation in the impact of KOA.
BACKGROUND: The optimal treatment of open fractures complicated by soft tissue loss of pediatric tibial fractures remains inconclusive. The author described a protocol of concurrent plate fixation and pedicled flap coverage and retrospectively reviewed the outcomes of such injuries.
METHODS: A total of 25 pediatric cases with Gustilo lllB open tibial fracture were treated by single-stage plate fixation and pedicled flap reconstruction. The reviewed information consisted of time to fix and flap, type of plate, type of pedicled flap, fracture union time, postoperative complication and the clinical outcomes by objective scoring system.
RESULTS: Fix and flap was undergone between 7 and 12 days after injury with the average time of 8.2 days. Regarding the type of plate, narrow LCP was applied in 8, 3.5 mm precontoured LCP in 10, 5.0 mm precontoured in 2 and double LCP in 5. According to soft tissue reconstruction, the medial gastrocnemius flap was selected in 6 cases, myocutaneous medial gastrocnemius flap in 2, soleus flap in 3, hemisoleus flap in 5, reverse sural flap in 6 and combined medial gastrocnemius and hemisoleus flaps in 3. No flap-related complication was demonstrated. All cases established fracture union in between 12 and 24 weeks with an average time to union of 17.7 weeks. According to postoperative complications, infected plate occurred in 2 cases and implant irritation in 5. According to Puno functional score, excellent results were presented in 7 cases and good results in 18 cases.
CONCLUSION: Single-stage plate fixation and pedicled flap coverage are a reliable regimen for pediatric open fractures complicated by soft tissue loss of the tibia.
Six genes whose expression is induced by leptin are disclosed (LIG46; LIG56;  Tgtp, encoding a T cell-specific GTP-binding protein; LRG-47, encoding an interferon (IFN) inducible protein; RC10-II, encoding a subunit of a 20S brain proteasome; and Stra13, encoding a retinoic acid inducible protein). These six leptin-inducible genes and the proteins they encode represent targets for the development of therapeutic agents for use in modulating body weight. For example, agents that alter the expression or activity of one or more of the leptin-induced proteins can be used to modulate body weight. Such agents can be identified using cellular, in vitro, or in vivo assays which monitor the expression or activity of one or more of the six leptin-induced proteins.  Potentially useful therapeutic agents can also be identified through the use of assays designed to identify agents that bind to one of the leptin-induced proteins. The leptin-induced genes of the invention and the proteins they encode may themselves be useful therapeutically and diagnostically.
ABSTRACT OF THE DISCLOSURE This invention pertains to a method of treating diseases caused by herpes viruses, including in particular Herpes Simplex Virus (HSV) Types 1 and 2.          Disclosed herein is a method of treatment that, through the use of Tetraethylammonium Ion (TEA), achieves a selective and specific inhibition of viral function in diseases caused by HSV 1 and 2. The TEA can be provided in the form of its choloride salt, unpreserved for individual doses, or with preservatives for multiple dose vials. The mechanism of action of TEA in this treatment is disclosed as that of a ganglionic blocker, and as such, TEA has the capability of limiting the duration of HSV induced disease and its recurrences by making mammalian cells impenetrable to the HSV 1 and 2.     (Patent App. Spec.              - Page 1 -      Joseph A. Baldone, M.D.)
The invention comprises water-soluble salts of a mercapto lower alkyl amine with a film-forming linear polymer of a water-soluble ethylenically unsaturated monomeric acid.  The acid is preferably acrylic acid although methacrylic, ethocrylic, maleic, itaconic, vinyl sulphuric or styrene sulphonic acids are specified. The term lower alkyl is used to mean alkyl groups containing up to 4 carbon atoms.  The exemplified amine is 2-mercaptoethyl amine although various primary, secondary and tertiary amines are specified. Polymer compositions comprise 2-mercaptoethyl ammonium polyacrylate in water together with glycerol, polyethylene glycol sorbiton monooleate, isopropyl palmitate and perfume.  The salt may be formed in situ.  The composition is used as a hair straightener.ALSO:A composition for treating hair or other keratin-containing fibre comprises a water-soluble salt of a mercapto lower alkyl amine with a film-forming linear polymer of a water-soluble ethylenically unsaturated monomeric acid, preferably 2-mercaptoethyl ammonium polyacrylate.  In addition to water the composition may also include glycerine, polyethylene glycol sorbitan monooleate, isopropyl palmitate, perfume and sodium hydroxid as a pH regulator.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The clinical trial database for NUPLAZID consists of over 1200 subjects and patients exposed to one or more doses of NUPLAZID. Of these, 616 were patients with hallucinations and delusions associated with Parkinson's disease psychosis (PDP). In the placebo-controlled setting, the majority of experience in patients comes from studies evaluating once-daily NUPLAZID doses of 34 mg (N=202) compared to placebo (N=231) for up to 6 weeks. In the controlled trial setting, the study population was approximately 64% male and 91% Caucasian, and the mean age was about 71 years at study entry. Additional clinical trial experience in patients with hallucinations and delusions associated with PDP comes from two open-label, safety extension studies (total N=497). The majority of patients receiving long-term treatment received 34 mg once-daily (N=459). Over 300 patients have been treated for more than 6 months; over 270 have been treated for at least 12 months; and over 150 have been treated for at least 24 months. 

The following adverse reactions are based on the 6-week, placebo-controlled studies in which NUPLAZID was administered once daily to patients with hallucinations and delusions associated with PDP. 

Common Adverse Reactions (incidence ≥5% and at least twice the rate of placebo): peripheral edema (7% NUPLAZID 34 mg vs. 2% placebo) and confusional state (6% NUPLAZID 34 mg vs. 3% placebo). 

Adverse Reactions Leading to Discontinuation of Treatment

A total of 8% (16/202) of NUPLAZID 34 mg-treated patients and 4% (10/231) of placebo-treated patients discontinued because of adverse reactions. The adverse reactions that occurred in more than one patient and with an incidence at least twice that of placebo were hallucination (2% NUPLAZID vs. <1% placebo), urinary tract infection (1% NUPLAZID vs. <1% placebo), and fatigue (1% NUPLAZID vs. 0% placebo). 

Adverse reactions that occurred in 6-week, placebo-controlled studies and that were reported at an incidence of ≥2% and >placebo are presented in Table 1. 

Adverse Reactions in Demographic Subgroups

Examination of population subgroups in the 6-week, placebo-controlled studies did not reveal any differences in safety on the basis of age (≤75 vs. >75 years) or sex. Because the study population was predominantly Caucasian (91%; consistent with reported demographics for PD/PDP), racial or ethnic differences in the safety profile of NUPLAZID could not be assessed. In addition, in the 6-week, placebo-controlled studies, no clinically relevant differences in the incidence of adverse reactions were observed among those with a Mini-Mental State Examination (MMSE) score at entry of <25 versus those with scores ≥25.
BACKGROUND AND AIMS: Compared to small vessel occlusion (SVO) patients, branch atheromatous disease (BAD) patients are more likely to develop early neurological deterioration (END). Stroke patients with END have a poor prognosis. Initial clinical features/radiological findings are often insufficient to distinguish between BAD and SVO; therefore, they may not detect END. In this retrospective study, we investigated relative factors for END in perforator artery infarction and created a scoring system for END in these patients.
METHODS: We extracted data from stroke patients with perforator artery infarction admitted to the Department of Neurology at Juntendo University between January 2016 and December 2022. We examined factors, such as the presence of SVO and BAD, leading to END. Variables with a P-value < 0.1 on univariate analysis were entered into binominal logistic regression analysis.
RESULTS: Of the 1,420 stroke patients admitted over a 7-year period, 201 with perforator infarction were included in this study. END was found in 27 of 201 patients (13.4%). Binominal logistic regression analysis of background factors less than p < 0.1 revealed that age > 69 (P = 0.032; odds ratio [OR], 3.941; 95% confidence interval [CI], 1.126-13.769), body mass index < 23.8 (P = 0.041; OR, 3.183; 95%CI, 1.049-9.654), and pretreatment with anti-platelets (P = 0.003; OR, 5.183; 95%CI, 1.783-15.071) were significant factors. Regarding anti-platelet therapy, END was observed in 34.4% of patients administered aspirin and 35.0% administered clopidogrel. Initial infarct lesion size over 15 mm on initial MRI had a P value of 0.076 in univariate analysis and an odds ratio of 1.330 (95% CI 0.471-3.755; P = 0.590) in binomial logistic regression analysis. The length of stay and modified Rankin Scale at discharge were significantly exacerbated in the END group. Creating a scoring system with 1 point for each relevant factor (pEND score), significant correlations were obtained with ROC curves, and over 2 points produced the highest sensitivity and specificity for detecting END.
CONCLUSION: Patients with high pEND scores may require intensive care from early hospitalization. In addition, the occurrence of stroke during anti-platelet therapy suggests the need for alternative treatment.
<P>PROBLEM TO BE SOLVED: To provide a water-in-oil emulsified formulation showing both stability and usability.  <P>SOLUTION: A cosmetic provided is the water-in-oil emulsified formulation that comprises at least two phases, i.e. a water-in-oil emulsified phase and an oil phase when standing still, but becomes homogeneous immediately after shaking. Oil phase components in the emulsified cosmetic comprise, based on the mass of the entire oil phase, 30-60 mass% volatile oil agent and 1-25 mass% aromatic liquid component and, based on the mass of the entire cosmetic, 0.5-2 mass% polyether-modified dimethicone serving as a surfactant. Preferably, the volatile oil agent is cyclomethicone or dimethicone, provided that the dimethicone has a viscosity of ≤5 mP×s.  <P>COPYRIGHT: (C)2010,JPO&INPIT